Renin-angiotensin system intervention to prevent in-stent restenosis - An unclosed chapterLangeveld, B., Roks, AJM., Tio, RA., Voors, AA., Zijlstra, F. & van Gilst, WH., Jan-2005, In : Journal of Cardiovascular Pharmacology. 45, 1, p. 88-98 11 p.
Research output: Contribution to journal › Review article › Academic › peer-review
The occurrence of in-stent restenosis is a major drawback of percutaneous transluminal coronary angioplasty with stent placement. Target vessel revascularization is necessary in 15% of patients who receive a stent. Recent advances in the development of drug-eluting stents have reduced these numbers tremendously. However refinement of antirestenotic therapies remains obligatory. The emerging interest in more physiological antirestenotic therapies might unchain an interest in the well-known inhibitors of the rennin-angiotensin system (RAS), the angiotensin-converting enzyme inhibitors, and the angiotensin II type I receptor blockers. Contradictory results overshadow the discussion of whether intervention in the RAS could prevent in-stent restenosis. This review discusses the pathophysiology of in-stent restenosis, the role of the RAS in in-stent restenosis, and the possible role of RAS intervention in the prevention of in-stent restenosis.
|Number of pages||11|
|Journal||Journal of Cardiovascular Pharmacology|
|Publication status||Published - Jan-2005|
- rennin-angiotensin system, stent, restenosis, CONVERTING ENZYME-INHIBITION, HUMAN CORONARY-ARTERIES, PLACEBO-CONTROLLED TRIAL, SIROLIMUS-ELUTING STENT, SERIAL INTRAVASCULAR ULTRASOUND, ENDOTHELIAL PROGENITOR CELLS, LEFT-VENTRICULAR DYSFUNCTION, CONGESTIVE-HEART-FAILURE, II RECEPTOR ANTAGONISTS, INDUCED VASCULAR INJURY